{"title_page": "Prohibitin-targeting peptide 1", "text_new": "{{Infobox drug\n| drug_name         =\n| INN               =\n| type              =<!-- empty -->\n| image             = \n| alt               = \n| caption           =\n<!-- Clinical data -->\n| pronounce         =\n| tradename         = Adipotide\n| Drugs.com         = \n| MedlinePlus       = \n| pregnancy_AU      = <!-- A/B1/B2/B3/C/D/X -->\n| pregnancy_AU_comment = \n| pregnancy_US      = <!-- A/B/C/D/X/N -->\n| pregnancy_category= \n| routes_of_administration = \n| ATCvet            = \n| ATC_prefix        = <!-- 'none' if uncategorised -->\n| ATC_suffix        = \n<!-- Legal data -->\n| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->\n| legal_AU_comment =\n| legal_BR =  <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F-->\n| legal_BR_comment =\n| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->\n| legal_DE = <!-- Anlage I, II, III -->\n| legal_NZ = <!-- Class A, B, C -->\n| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->\n| legal_US = <!-- OTC/Rx-only/Schedule I, II, III, IV, V -->\n| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV-->\n| legal_status      = Investigational\n<!-- Pharmacokinetic data -->\n| bioavailability   = \n| protein_bound     = \n| metabolism        = \n| metabolites       =\n| onset             = \n| elimination_half-life = \n| duration_of_action =\n| excretion         = \n<!-- Identifiers -->\n| IUPAC_name        = \n| CAS_number        = \n| PubChem           = \n| DrugBank          = \n| synonyms          = Prohibitin-TP01; TP01\n<!-- Chemical and physical data -->\n| chemical_formula  = \n| molecular_weight  = \n}}\n\n'''Prohibitin-targeting peptide 1''' (also known as '''prohibitin-TP01''' and '''TP01'''; trade name '''Adipotide''') is a [[peptidomimetic]] with [[Peptide sequence|sequence]] CKGGRAKDC-GG-<sub>D</sub>(KLAKLAK)<sub>2</sub>.  It is an experimental [[proapoptotic]] drug<ref>{{Cite web | url = https://www.cancer.gov/publications/dictionaries/cancer-drug/def/prohibitin-targeting-peptide-1 | title = Prohibitin-targeting peptide 1 | work = NCI Drug Dictionary | date = 2 February 2011 | publisher = National Cancer Institutes }}</ref> that has been shown to cause rapid weight loss in mice<ref name=\"miceablation\">{{cite journal | vauthors = Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W | title = Reversal of obesity by targeted ablation of adipose tissue | journal = Nature Medicine | volume = 10 | issue = 6 | pages = 625\u201332 | date = June 2004 | pmid = 15133506 | doi = 10.1038/nm1048 | publisher = Nature Publishing Group }}</ref> and rhesus monkeys.<ref name=\"zipblood\">{{cite web |url=http://medicalxpress.com/news/2011-10-blood-vessel-reveals-codes.html |title=Blood vessel mapping reveals four new 'ZIP codes' |author=|date=24 October 2011 |publisher=medicalxpress |access-date=10 November 2011}}</ref> Its mechanism of action is to target specific blood vessels supplying adipose tissue with blood, cause the vessels to shrink and the fat cells fed by those vessels to undergo [[apoptosis]].<ref name=\"obese monkeys\">{{cite journal | vauthors = Barnhart KF, Christianson DR, Hanley PW, Driessen WH, Bernacky BJ, Baze WB, Wen S, Tian M, Ma J, Kolonin MG, Saha PK, Do KA, Hulvat JF, Gelovani JG, Chan L, Arap W, Pasqualini R | display-authors = 6 | title = A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys | journal = Science Translational Medicine | volume = 3 | issue = 108 | pages = 108ra112 | date = November 2011 | pmid = 22072637 | pmc = 3666164 | doi = 10.1126/scitranslmed.3002621 }}</ref> TP01 is designed to bind to two receptors, [[ANXA2]] and [[prohibitin]], that are specific to blood vessels supplying [[white adipose tissue]].<ref name=\"29authors\">{{cite journal | vauthors = Staquicini FI, Card\u00f3-Vila M, Kolonin MG, Trepel M, Edwards JK, Nunes DN, Sergeeva A, Efstathiou E, Sun J, Almeida NF, Tu SM, Botz GH, Wallace MJ, O'Connell DJ, Krajewski S, Gershenwald JE, Molldrem JJ, Flamm AL, Koivunen E, Pentz RD, Dias-Neto E, Setubal JC, Cahill DJ, Troncoso P, Do KA, Logothetis CJ, Sidman RL, Pasqualini R, Arap W | display-authors = 6 | title = Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 108 | issue = 46 | pages = 18637\u201342 | date = November 2011 | pmid = 22049339 | pmc = 3219136 | doi = 10.1073/pnas.1114503108 | bibcode = 2011PNAS..10818637S | doi-access = free }}</ref>\n\nAs of 2019, clinical development has been discontinued.<ref>{{Cite web | url = https://adisinsight.springer.com/drugs/800035229 | title = Prohibitin targeting peptide 1 | work = Adis Insight | publisher = Springer Nature Switzerland AG }}</ref>\n\n== References ==\n{{Reflist|2}}\n\n{{Extracellular chemotherapeutic agents}}\n{{Signaling peptide/protein receptor modulators}}\n\n[[Category:Angiogenesis inhibitors]]\n[[Category:Antiobesity drugs]]\n[[Category:Receptor antagonists]]\n[[Category:Abandoned drugs]]\n", "text_old": "{{Infobox drug\n| drug_name         =\n| INN               =\n| type              =<!-- empty -->\n| image             = \n| alt               = \n| caption           =\n<!-- Clinical data -->\n| pronounce         =\n| tradename         = Adipotide\n| Drugs.com         = \n| MedlinePlus       = \n| pregnancy_AU      = <!-- A/B1/B2/B3/C/D/X -->\n| pregnancy_AU_comment = \n| pregnancy_US      = <!-- A/B/C/D/X/N -->\n| pregnancy_category= \n| routes_of_administration = \n| ATCvet            = \n| ATC_prefix        = <!-- 'none' if uncategorised -->\n| ATC_suffix        = \n<!-- Legal data -->\n| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->\n| legal_AU_comment =\n| legal_BR =  <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F-->\n| legal_BR_comment =\n| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->\n| legal_DE = <!-- Anlage I, II, III -->\n| legal_NZ = <!-- Class A, B, C -->\n| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->\n| legal_US = <!-- OTC/Rx-only/Schedule I, II, III, IV, V -->\n| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV-->\n| legal_status      = Investigational\n<!-- Pharmacokinetic data -->\n| bioavailability   = \n| protein_bound     = \n| metabolism        = \n| metabolites       =\n| onset             = \n| elimination_half-life = \n| duration_of_action =\n| excretion         = \n<!-- Identifiers -->\n| IUPAC_name        = \n| CAS_number        = \n| PubChem           = \n| DrugBank          = \n| synonyms          = Prohibitin-TP01; TP01\n<!-- Chemical and physical data -->\n| chemical_formula  = \n| molecular_weight  = \n}}\n\n'''Prohibitin-targeting peptide 1''' (also known as '''prohibitin-TP01''' and '''TP01'''; trade name '''Adipotide''') is a [[peptidomimetic]] with [[Peptide sequence|sequence]] CKGGRAKDC-GG-<sub>D</sub>(KLAKLAK)<sub>2</sub>.  It is an experimental [[proapoptotic]] drug<ref>{{Cite web | url = https://www.cancer.gov/publications/dictionaries/cancer-drug/def/prohibitin-targeting-peptide-1 | title = Prohibitin-targeting peptide 1 | work = NCI Drug Dictionary | date = 2 February 2011 | publisher = National Cancer Institutes }}</ref> that has been shown to cause rapid weight loss in mice<ref name=\"miceablation\">{{cite journal | vauthors = Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W | title = Reversal of obesity by targeted ablation of adipose tissue | journal = Nature Medicine | volume = 10 | issue = 6 | pages = 625\u201332 | date = June 2004 | pmid = 15133506 | doi = 10.1038/nm1048 | publisher = Nature Publishing Group }}</ref> and rhesus monkeys.<ref name=\"zipblood\">{{cite web |url=http://medicalxpress.com/news/2011-10-blood-vessel-reveals-codes.html |title=Blood vessel mapping reveals four new 'ZIP codes' |author=|date=24 October 2011 |publisher=medicalxpress |access-date=10 November 2011}}</ref> Its mechanism of action is to target specific blood vessels supplying adipose tissue with blood, cause the vessels to shrink and the fat cells fed by those vessels to undergo [[apoptosis]].<ref name=\"obese monkeys\">{{cite journal | vauthors = Barnhart KF, Christianson DR, Hanley PW, Driessen WH, Bernacky BJ, Baze WB, Wen S, Tian M, Ma J, Kolonin MG, Saha PK, Do KA, Hulvat JF, Gelovani JG, Chan L, Arap W, Pasqualini R | display-authors = 6 | title = A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys | journal = Science Translational Medicine | volume = 3 | issue = 108 | pages = 108ra112 | date = November 2011 | pmid = 22072637 | pmc = 3666164 | doi = 10.1126/scitranslmed.3002621 }}</ref> TP01 is designed to bind to two receptors, [[ANXA2]] and [[prohibitin]], that are specific to blood vessels supplying [[white adipose tissue]].<ref name=\"29authors\">{{cite journal | vauthors = Staquicini FI, Card\u00f3-Vila M, Kolonin MG, Trepel M, Edwards JK, Nunes DN, Sergeeva A, Efstathiou E, Sun J, Almeida NF, Tu SM, Botz GH, Wallace MJ, O'Connell DJ, Krajewski S, Gershenwald JE, Molldrem JJ, Flamm AL, Koivunen E, Pentz RD, Dias-Neto E, Setubal JC, Cahill DJ, Troncoso P, Do KA, Logothetis CJ, Sidman RL, Pasqualini R, Arap W | display-authors = 6 | title = Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 108 | issue = 46 | pages = 18637\u201342 | date = November 2011 | pmid = 22049339 | pmc = 3219136 | doi = 10.1073/pnas.1114503108 | bibcode = 2011PNAS..10818637S | doi-access = free }}</ref>\n\nAs of 2019, clinical development has been discontinued.<ref>{{Cite web | url = https://adisinsight.springer.com/drugs/800035229 | title = Prohibitin targeting peptide 1 | publisher = Adis Insight }}</ref>\n\n== References ==\n{{Reflist|2}}\n\n{{Extracellular chemotherapeutic agents}}\n{{Signaling peptide/protein receptor modulators}}\n\n[[Category:Angiogenesis inhibitors]]\n[[Category:Antiobesity drugs]]\n[[Category:Receptor antagonists]]\n[[Category:Abandoned drugs]]\n", "name_user": "Boghog", "label": "safe", "comment": "added missing data to cite", "url_page": "//en.wikipedia.org/wiki/Prohibitin-targeting_peptide_1"}
